- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01144156
Small Bowel Mucosal Healing Induced by Adalimumab in Crohn's Disease Patients as Assessed by Capsule Endoscopy
June 14, 2010 updated by: Rabin Medical Center
The study hypothesis is that adalimumab induces mucosal healing in the small bowel and that mucosal healing correlates with disease activity.
30 Patients with isolated active small bowel Crohn's disease which are candidates to receive anti-TNF treatment will be included in the study.
All patients will undergo patency capsule examination and capsule endoscopy afterwards.
Small bowel endoscopic disease severity will be assessed by the capsule endoscopy Crohn's disease activity index (CECDAI).
The patients will receive Adalimumab (Humira)injections (160mg,80mg and 40mg every 2 weeks ) for 12 weeks.
on week 14 a second capsule endoscopy will be performed and CECDAI calculated again.
The patients clinical condition, CDAI,IBDQ and laboratory results including CRP, CBC and fecal calprotectin will be assessed on weeks o, 7 and 14 and results will be compared with the endoscopic score.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Petach Tikva, Israel, 4910
- Rabin Medical Center - Beilinson Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Isolated small bowel Crohn's disease.
- Age ≥18.
- Active disease (CDAI≥220).
Exclusion Criteria:
- Known fixed stricture in the small intestine.
- Former small bowel obstruction or obstructive symptoms.
- Patients expected to undergo small bowel surgery in the near future or had intestinal surgery in the previous 6 months.
- Colonic disease (except ileocecal valve area).
- Anti-TNF treatment in the last 3 months.
- Sensitivity or lack of response to previous adalimumab treatment.
- Current gastrointestinal infection.
- History of malignant disease (except BCC of skin).
- Congestive heart failure, severe renal or hepatic dysfunction.
- Patients suffering from tuberculosis, hepatitis B or C.
- Pregnancy or unwillingness to use contraception during study period.
- Dysphagia or swallowing disorders
- Gastroparesis or severe gastrointestinal motility dysfunction.
- Patients with cardiac pacemaker or implanted cardioverter devices.
- Unable to sign informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete mucosal healing
Time Frame: After 14 weeks of treatment
|
Complete mucosal healing of active inflammatory lesions in the small intestine, as assessed by capsule endoscopy
|
After 14 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Partial mucosal healing
Time Frame: After 14 weeks of treatment
|
Reduction of at least 50% in the Capsule Endoscopy Crohn's Disease Activity Index (CECDAI) after treatment.
|
After 14 weeks of treatment
|
Correlation with clinical activity
Time Frame: After 14 weeks of treatment
|
Statistical correlation between CECDAI reduction and reduction in clinical (CDAI, IBDQ) and laboratory (CRP, calprotectin etc.) indices of disease activity.
|
After 14 weeks of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
June 13, 2010
First Submitted That Met QC Criteria
June 14, 2010
First Posted (Estimate)
June 15, 2010
Study Record Updates
Last Update Posted (Estimate)
June 15, 2010
Last Update Submitted That Met QC Criteria
June 14, 2010
Last Verified
May 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Gal002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn's Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Massachusetts General HospitalAmerican College of GastroenterologyNot yet recruitingInflammatory Bowel Diseases | Crohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's EsophagitisUnited States
-
Richard Burt, MDTerminatedCROHN'S DISEASEUnited States
-
Agomab Spain S.L.RecruitingFibrostenotic Crohn's DiseaseUnited States, Italy, Poland, Spain, Denmark, Austria, Canada, Germany
-
AbbVieActive, not recruitingCrohn's Disease (CD)United States, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Romania, Slovakia, Spain, United Kingdom
-
AbbVieActive, not recruitingCrohn's Disease (CD)United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Slo... and more
-
University Hospital, LilleMinistry of Health, FranceTerminatedCrohn's Disease AggravatedFrance
-
TakedaRecruitingCrohn's Disease (CD)United States, Australia, Israel, Belgium, Hungary, Canada, China, Croatia, Czechia, Greece, Italy, Japan, Korea, Republic of, Poland, United Kingdom, Lithuania, Slovakia, Spain
-
Weill Medical College of Cornell UniversityThe Kenneth Rainin FoundationRecruitingCrohn's Disease (CD)United States
Clinical Trials on Treatment with Adalimumab
-
University of Western Ontario, CanadaPrometheus LaboratoriesTerminatedCrohn's Disease | Ulcerative ColitisUnited States
-
Medical University of ViennaUnknownCardiovascular Diseases | Diabetes Mellitus, Type 2 | PsoriasisAustria
-
Assistance Publique Hopitaux De MarseilleRecruitingRasmussen EncephalitisFrance
-
Vanderbilt University Medical CenterCompletedCrohn Disease | Rectal FistulaUnited States
-
Innovaderm Research Inc.Abbott; Montreal Heart InstituteCompletedPsoriasis | Coronary Atherosclerosis | Vascular InflammationCanada
-
University Hospital, BordeauxEli Lilly and Company; Biogen; Ministry for Health and Solidarity, FranceRecruitingRheumatoid ArthritisFrance, Monaco
-
PfizerCompletedHealthyUnited States, Belgium
-
Universidad Complutense de MadridRecruitingMalocclusion, Angle Class II | DistalizationSpain
-
PfizerCompletedHealthy SubjectsUnited States
-
Helsinki University Central HospitalActive, not recruitingto Omit Radioiodine Treatment Safely in Patients With Low -Risk Papillary Thyroid Cancer With Seize of 11-20mm